Tara Arvedson
Chief Scientific Officer Hexagon Bio
Seminars
Tuesday 13th October 2026
Spotlighting Novel Payloads & Payload Combinations for Next-Generation ADCs
3:30 pm
- Contextualizing the urgent need for new payloads to address clinical resistance and Hexagon Bio's proprietary natural product collection combined with small molecule engineering to produce a best-in-class translation inhibitor (TI) payload
- Breaking down HEX-360, an anti-HER2 antibody-TI conjugate, exhibiting strong anti-tumor activity in resistant settings and a favorable differentiated safety profile
- Reporting further demonstration of the TI payload conjugated in mono and dual payload formats to illustrate the broad applicability of the new TI payload
